By Dave Sebastian

 

Bristol Myers Squibb said it has received positive opinion for Opdivo, its treatment of esophageal or gastroesophageal junction cancer, from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

The company on Friday said the European Commission, which has the authority to approve medicines, will now review the recommendation.

The committee's positive opinion is based on a phase three trial of Opdivo, Bristol Myers Squibb said.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

June 25, 2021 07:30 ET (11:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Bristol Myers Squibb Charts.